Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 21 April 2015 | By Alexander Gaffney, RAC,
Regulators and generic pharmaceutical companies, start your engines. The race to the next reauthorization of the Generic Drug User Fee Act (GDUFA) has begun.
In a Federal Register notice on 21 April 2015, the US Food and Drug Administration (FDA) announced that it will begin accepting comments regarding the first-ever reauthorization of GDUFA—a user fee arrangement which funds much of FDA's generic pharmaceutical regulatory activities.
GDUFA was first passed into law in 2012 under the Food and Drug Administration Safety and Innovation Act (FDASIA)—a massive piece of legislation which contained hundreds of reform measures and several user fee components meant to increase funding for FDA.
GDUFA, which is modeled off similar user fee programs for pharmaceuticals (PDUFA) and medical devices (MDUFA), is built around a simple premise. Generic drug companies would like to see their products approved more quickly. FDA is capable of approving drug products more quickly, but not without a sizeable increase in staff and improvements to its regulatory infrastructure.
GDUFA bridges this gap by requiring generic pharmaceutical companies to pay a fee to FDA for many of its routine activities, including generic drug filings and manufacturing facility inspections.
In return, FDA commits to reviewing generic drug applications within a certain time frame, which allows generic drug companies to—in theory—bring their products to market more quickly. The first authorization of GDUFA also contained extra money for FDA to reduce a massive backlog of generic drug applications that were slowing down drug approvals.
Read our extensive coverage of GDUFA here.
Now, nearly four years after GDUFA was first passed into law and with GDUFA creeping up on its 2017 date of expiry, FDA is starting up the reauthorization process for GDUFA II.
FDA's reauthorization processes are by any measure extraordinarily unusual. With the exception of trade agreements, Congress is typically the first and last word in any agreement between a government agency and the industries it regulates. But that's not the case with FDA's user fee agreements, which are hashed out in direct negotiations between FDA and each of the respective industries it regulates. Congress is then given the draft of the user fee bill for final approval.
Stakeholders involved in the negotiating process for past user fee agreements have said this process results in an agreement that is tenable for both parties, and prevents the user fee agreements from becoming politicized or heavily modified by legislators lacking a deep understanding of the drug approvals process.
The reauthorization process is also controlled in part by federal legislation, the Federal Food, Drug and Cosmetic Act, which requires FDA to request "public input on the reauthorization" prior to starting any negotiations with industry. In addition, FDA is required to hold a public meeting, during which time the public may comment on the reauthorization process and recommend changes to be made to the upcoming user fee agreement and accompanying Commitment Letter, which describes in detail the commitments to be carried out by FDA.
In particular, FDA asks two questions of the public:
As noted by Bob Pollock, former acting deputy director of the Office of Generic Drugs, major issues expected to be brought up during the GDUFA reauthorization process are the number of generic drugs approved, the communication of application status after approval, the quality of some generic drug applications, and the financial resources available for a new user fee agreement.
FDA's GDUFA meeting will take place on 15 June 2015 on FDA's White Oak campus in Silver Spring, MD.
Federal Register Notice
Tags: GDUFA, Generic Drug User Fee Act, Office of Generic Drugs
Regulatory Focus newsletters
All the biggest regulatory news and happenings.